Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 28;17(7):e0264566.
doi: 10.1371/journal.pone.0264566. eCollection 2022.

The percentage of CD39+ monocytes is higher in pregnant COVID-19+ patients than in nonpregnant COVID-19+ patients

A Cérbulo-Vázquez  1 , M García-Espinosa  2 , J C Briones-Garduño  3 , L Arriaga-Pizano  4 , E Ferat-Osorio  5 , B Zavala-Barrios  3 , G L Cabrera-Rivera  4 , P Miranda-Cruz  4 , M T García de la Rosa  4 , J L Prieto-Chávez  4   6 , V Rivero-Arredondo  4 , R L Madera-Sandoval  4 , A Cruz-Cruz  4 , E Salazar-Rios  4 , M E Salazar-Rios  4 , D Serrano-Molina  4 , R C De Lira-Barraza  4 , A H Villanueva-Compean  7 , A Esquivel-Pineda  7 , R Ramirez-Montes de Oca  7 , F Caldiño-Soto  8 , L A Ramírez-García  9 , G Flores-Padilla  7 , O Moreno-Álvarez  9 , G M L Guerrero-Avendaño  10 , C López-Macías  4   11
Affiliations

The percentage of CD39+ monocytes is higher in pregnant COVID-19+ patients than in nonpregnant COVID-19+ patients

A Cérbulo-Vázquez et al. PLoS One. .

Abstract

Current medical guidelines consider pregnant women with COVID-19 to be a high-risk group. Since physiological gestation downregulates the immunological response to maintain "maternal-fetal tolerance", SARS-CoV-2 infection may constitute a potentially threatening condition to both the mother and the fetus. To establish the immune profile in pregnant COVID-19+ patients, a cross-sectional study was conducted. Pregnant women with COVID-19 (P-COVID-19+; n = 15) were analyzed and compared with nonpregnant women with COVID-19 (NP-COVID-19+; n = 15) or those with physiological pregnancy (P-COVID-19-; n = 13). Serological cytokine and chemokine concentrations, leucocyte immunophenotypes, and mononuclear leucocyte responses to polyclonal stimuli were analyzed in all groups. Higher concentrations of serological TNF-α, IL-6, MIP1b and IL-4 were observed within the P-COVID-19+ group, while cytokines and chemokines secreted by peripheral leucocytes in response to LPS, IL-6 or PMA-ionomicin were similar among the groups. Immunophenotype analysis showed a lower percentage of HLA-DR+ monocytes in P-COVID-19+ than in P-COVID-19- and a higher percentage of CD39+ monocytes in P-COVID-19+ than in NP-COVID-19+. After whole blood polyclonal stimulation, similar percentages of T cells and TNF+ monocytes between groups were observed. Our results suggest that P-COVID-19+ elicits a strong inflammatory response similar to NP-COVID19+ but also displays an anti-inflammatory response that controls the ATP/adenosine balance and prevents hyperinflammatory damage in COVID-19.

PubMed Disclaimer

Conflict of interest statement

All authors declare no competing interests.

Figures

Fig 1
Fig 1. Surface marker on leucocytes.
Whole blood cells were immunophenotyped as described in the methods. The results are expressed as the mean±SD. Significance value was p<0.05. Kruskal–Wallis and Dunn’s multiple comparisons tests were calculated. Non-Pregnant COVID-19 positive (NP-COVID-19+, n = 4–9). Pregnant COVID-19 positive (P-COVID-19+, n = 10–15). Pregnant COVID-19 negative (P-COVID-19-, n = 12–13). The dotted line indicates the percentage of monocytes, B cells and T cells that constitutively express CD39 [32].
Fig 2
Fig 2. Percentage of cytokine-positive leucocytes.
Whole blood cells were immunophenotyped as described in the methods. The results are expressed as the mean±SD. Significance value was p<0.05. Kruskal–Wallis and Dunn’s multiple comparisons tests were calculated. Non-Pregnant COVID-19 positive (NP-COVID-19+, n = 5–6). Pregnant COVID-19 positive (P-COVID-19+, n = 12–15). Pregnant COVID-19 negative (P-COVID-19-, n = 12–13).
Fig 3
Fig 3. Cytokine/chemokine serum concentration.
Serum was isolated, and cytokine/chemokine concentrations were determined using bead-based immunoassays as described in the methods. The results are expressed as the mean±SD. Significance value was p<0.05. Kruskal–Wallis and Dunn’s multiple comparisons tests were calculated. Non-Pregnant COVID-19 positive (NP-COVID-19+, n = 13). Pregnant COVID-19 positive (P-COVID-19+, n = 14–15). Pregnant COVID-19 negative (P-COVID-19-, n = 13).
Fig 4
Fig 4. Cytokine/chemokine response after 4 hours of culture with polyclonal stimulus in pregnant and nonpregnant women with or without COVID-19.
The supernatant was collected, and cytokine/chemokine concentrations were determined using bead-based immunoassays as described in the methods. The results are expressed as the mean±SD. Significance value was p<0.05. Kruskal–Wallis and Dunn’s multiple comparisons tests were calculated. Non-Pregnant COVID-19 positive (NP-COVID-19+, n = 3). Pregnant COVID-19 positive (P-COVID-19+, n = 8–10). Pregnant COVID-19 negative (P-COVID-19-, n = 12). WB, Whole Blood.
See this image and copyright information in PMC

References

    1. Berhan Y. What immunological and hormonal protective factors lower the risk of COVID-19 related deaths in pregnant women? J Reprod Immunol. 2020;142:103180. Epub 2020/08/03. doi: 10.1016/j.jri.2020.103180 - DOI - PMC - PubMed
    1. Villar J, Ariff S, Gunier RB, Thiruvengadam R, Rauch S, Kholin A, et al.. Maternal and Neonatal Morbidity and Mortality Among Pregnant Women With and Without COVID-19 Infection: The INTERCOVID Multinational Cohort Study. JAMA Pediatr. 2021. Epub 2021/04/23. doi: 10.1001/jamapediatrics.2021.1050 - DOI - PMC - PubMed
    1. Zambrano LD, Ellington S, Strid P, Galang RR, Oduyebo T, Tong VT, et al.. Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status—United States, January 22-October 3, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(44):1641–7. Epub 2020/11/06. doi: 10.15585/mmwr.mm6944e3 - DOI - PMC - PubMed
    1. Delahoy MJ, Whitaker M, O’Halloran A, Chai SJ, Kirley PD, Alden N, et al.. Characteristics and Maternal and Birth Outcomes of Hospitalized Pregnant Women with Laboratory-Confirmed COVID-19—COVID-NET, 13 States, March 1-August 22, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(38):1347–54. Epub 2020/09/25. doi: 10.15585/mmwr.mm6938e1 - DOI - PMC - PubMed
    1. Silasi M, Cardenas I, Kwon JY, Racicot K, Aldo P, Mor G. Viral infections during pregnancy. Am J Reprod Immunol. 2015;73(3):199–213. Epub 2015/01/15. doi: 10.1111/aji.12355 - DOI - PMC - PubMed

Publication types